甲状腺癌淋巴结转移的CT表现

目的：评价甲状腺癌淋巴结转移的CT特点。方法：回顾性分析经手术及病理诊断的108例甲状腺癌淋巴结转移的CT表现。结果：108例中，颈上中深组淋巴结转移76例，颈下深组及锁骨上窝86例，气管食管沟52例，纵隔17例。84例乳头状癌中，16例淋巴结密度与正常甲状腺相似，24例有囊性变，其中18例淋巴结囊内有明显强化的乳头状结节，11例有细颗粒状钙化，24例滤泡癌，髓样癌，透明细胞癌中，17例淋巴结明显强化，17例与甲状腺原发或复发肿瘤密度一致，密度均匀或不均匀。结论：甲状腺癌转移淋巴结好发部位为颈静脉链周围，气管食管沟及纵隔；淋巴结明显强化，与正常甲状腺密度一致，囊性变，囊壁内明显强化的乳头状结节及细颗粒状钙化为甲状腺乳头状癌的特征性改变，淋巴结明显强化，与甲状腺肿瘤密度一致为滤泡癌，髓样癌，透明细胞癌转移淋巴结的特点。

CT manifestations of lymph node metastasis of thyroid carcinoma

Objective To study the CT manifestations of metastatic lymph node of thyroid carcinoma. Methods CT appearances of metastatic lymph node of thyroid carcinoma proved by surgery and pathology in 108 patients were reviewed. Results Of these 108 cases, metastatic lymph nodes were located at superoir and middle internal jugular chain(n=76), inferior internal jugular chain and super clavicular region(n=86), tracheoesophageal groove(n=52), and superior mediastinum(n=17). Of 84 thyroid papillary carcinoma patients, the attenuation of metastatic lymph nodes were similar to that of normal thyroid gland(n=16), with cystic formations (n=24), intracystic high attenuation papillary-like nodules (n=18), and fine granular calcifications (n=11). Of 24 follicular carcinoma, medullary carcinoma, and clear cell carcinoma patients, 17 cases had significant homogeneous or heterogeneous enhanced nodes, and the attenuation was the same as primary or recurrent thyroid tumors. Conclusion For thyroid carcinoma, the most common locations of metastatic lymph nodes were internal jugular chain, tracheoesophageal groove, and superior mediastinum regions. Marked enhancement similar to normal thyroid gland, cystic formations with intracystic high attenuation papillary-like nodules, and fine discrete granular calcifications were the characteristic manifestations of metastatic lymph node of papillary carcinoma. Marked homogeneous or heterogeneous enhancement after contrast administration and the same attenuation as the primary or recurrent thyroid tumor were found in follicular carcinoma, medullary carcinoma, and clear cell carcinoma metastases.